A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Public ClinicalTrials.gov record NCT03886831. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.
Study identification
- NCT ID
- NCT03886831
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 232 participants
Conditions and interventions
Conditions
- Relapsed/Refractory Advanced Solid Tumors
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Relapsed/Refractory Myelodysplasia
- Relapsed/Refractory Myelofibrosis
- Adenoid Cystic Carcinoma
- Relapsed/Refractory Mantle Cell Lymphoma
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Chronic Myelomonocytic Leukemia
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2019 (Actual)
- Primary completion
- Nov 16, 2022 (Actual)
- Completion
- Nov 16, 2022 (Actual)
- Last update posted
- Mar 28, 2023
2019 – 2022
United States locations
- U.S. sites
- 23
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| UCSF Precision Cancer Medicine Building | San Francisco | California | 94158 | — |
| Christiana Care Health Services, Christiana Hospital | Newark | Delaware | 19718 | — |
| Florida Cancer Specialists | Lake Mary | Florida | 32746 | — |
| Florida Cancer Specialist | Sarasota | Florida | 34232 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Atlantic Health System / Morristown Medical Center | Morristown | New Jersey | 07962 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| The Ohio State University and Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| PLLC | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03886831, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03886831 live on ClinicalTrials.gov.